| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CHEK1; CHK1; Serine/threonine-protein kinase Chk1; CHK1 checkpoint homolog; Cell cycle checkpoint kinase; Checkpoint kinase-1 |
| Entrez GeneID | 1111 |
| WB Predicted band size | Calculated MW: 54 kDa; Observed MW: 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human Chk1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4条关于Chk1抗体的参考文献及其简要摘要：
---
1. **文献名称**: *"CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway defects"*
**作者**: Zhou et al.
**摘要**: 研究验证了Chk1抗体在乳腺癌细胞模型中的作用，发现Chk1抑制剂通过阻断DNA损伤修复增强化疗敏感性，Western blot实验中Chk1抗体成功检测到磷酸化Chk1水平变化。
---
2. **文献名称**: *"Targeting the cell cycle checkpoint kinase Chk1 in cancer therapy"*
**作者**: Smith et al.
**摘要**: 探讨了Chk1作为癌症治疗靶点的潜力，使用特异性Chk1抗体(如DCS-310)进行免疫组化分析，显示Chk1高表达与患者预后不良相关，支持其作为生物标志物。
---
3. **文献名称**: *"Regulation of the Chk1-Cdc25A pathway by the DNA damage response kinase ATM"*
**作者**: Takai et al.
**摘要**: 通过Chk1抗体(如鼠抗人Chk1单克隆抗体)研究ATM激酶对Chk1的调控机制，发现DNA损伤后Chk1磷酸化依赖ATM激活，抗体验证了其在细胞周期停滞中的关键作用。
---
4. **文献名称**: *"Preclinical evaluation of Chk1 inhibitors in combination with genotoxic therapies"*
**作者**: Thompson & Eastman
**摘要**: 评估Chk1抑制剂联合化疗的疗效，利用Chk1抗体(如AB-1340)检测肿瘤组织中Chk1活性抑制情况，证明抗体在药效学分析中的可靠性。
---
**说明**：以上为示例文献(部分内容基于真实研究整合，非直接引用原文)，实际引用时需根据具体文献补充完整信息。Chk1抗体相关研究多聚焦于其在DNA损伤响应、癌症治疗及细胞周期调控中的应用。
Chk1 (Checkpoint kinase 1) is a serine/threonine kinase critical for maintaining genomic stability during DNA replication and cell division. It plays a central role in the DNA damage response (DDR) by regulating cell cycle checkpoints, particularly the G2/M checkpoint. Upon DNA damage or replication stress, Chk1 is activated via phosphorylation by upstream kinases like ATR (ataxia-telangiectasia and Rad3-related), leading to cell cycle arrest, DNA repair facilitation, or apoptosis if damage is irreparable. Dysregulation of Chk1 is linked to genomic instability and cancer progression, making it a potential therapeutic target.
Chk1 antibodies are essential tools for studying its expression, activation, and functional roles. They are widely used in techniques such as Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation to detect Chk1 protein levels, phosphorylation status (e.g., at Ser317 or Ser345), and interactions with other DDR components. Commercial Chk1 antibodies are typically raised against specific epitopes, with validation in diverse sample types (cell lysates, tissues). Researchers must verify antibody specificity due to potential cross-reactivity with related kinases (e.g., Chk2).
In cancer research, Chk1 inhibitors combined with DNA-damaging agents are explored to sensitize tumor cells, exploiting Chk1's role in checkpoint control. Thus, Chk1 antibodies are pivotal for both mechanistic studies and drug development in oncology.
×
